MedTrace Logo

Mix Vaccine for Metastatic Sarcoma Patients

NCT03357315 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-09-12

No results posted yet for this study

Summary

The aim of this study is the safety and efficacy of mix vaccine to small metastases of sarcoma.

Conditions

  • Metastatic Sarcoma
  • Reaction - Mixed Vaccine

Interventions

BIOLOGICAL

Mix vaccine

Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle

Sponsors & Collaborators

  • Jinan University Guangzhou

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-30
Primary Completion
2018-11-30
Completion
2019-08-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03357315 on ClinicalTrials.gov